

## HLA-A\*11:01&amp;B2M&amp;KRAS G12D (VVVGADGVGK) Monomer Protein, Human, MHC (His)

## General Information

|                       |  |
|-----------------------|--|
| Synonyms:             | KRAS1;KI-RAS;NS3;K-RAS2B;KRAS;K-RAS2A;KRAS2;NS;K-Ras 2;RALD;RASK2;K-RAS4A;CFC2;MHC;C-K-RAS;K-RAS4B;GTPase Kras |
| Protein Construction: | Gly25-Thr305 (HLA-A*11:01), Ile21-Met119 (B2M) and VVVGADGVGK peptide  |
| Species:              | Human  |
| Expression Host:      | HEK293 Cells   |
| Accession:            | AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGADGVGK   |
| Molecular Weight:     | 48.40 kDa (Predicted); 50-60 kDa (Reducing condition, due to glycosylation)                                    |

## QC Testing

|                      |  |
|----------------------|--|
| Biological Activity: | Immobilized HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) TCR at 5 µg/ml (100 µl/well) on the plate. Dose response curve for Human HLA-A*11:01&B2M&KRAS G12D (VVVGADGVGK) Monomer, His Tag with the EC50 of 59.4 ng/ml determined by ELISA (QC Test). |
| Purity:              | > 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC  |
| Endotoxin:           | < 1 EU/µg of the protein as determined by the LAL method.  |
| Formulation:         | Supplied as 0.22 µm filtered solution in PBS (pH 7.4).   |

## Preparation and Storage

## Stability &amp; Storage:

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Actual storage temperature shall be subject to the COA.

## Shipping:

In general, lyophilized powders are shipped with blue ice, while solutions are shipped with dry ice.

## Protein Background

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

**This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use**

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481